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Abstract
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Minimally invasive surgery for gynecologic cancers is associated with fewer postoperative
complications including less blood loss and quicker recovery time compared to traditional
laparotomy. The robotic platform has allowed patients access to minimally invasive surgery due to
its increased utilization by gynecologic oncologists. Many surgeons have embraced the robotic
platform due to its technological advances over traditional laparoscopy including high-definition
3D optics, wristed instrumentation, camera stability and improved ergonomics. While robotic
surgery continues as a mainstay in the management of gynecologic cancers, it remains
controversial in regards to its cost effectiveness and more recently, its long-term impact on clinical
and oncologic outcomes. A strong component of the justification of this surgical platform is based
on extrapolated data from traditional laparoscopy despite limited prospective randomized trials for
robotic-assisted surgery. In this review, we highlight the use of robotic surgery in the management
of gynecologic cancers in special populations: fertility sparing patients, the morbidly obese, the
elderly, and patients with a favorable response to neoadjuvant chemotherapy.
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Historical Notes
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It is best estimated that Leonardo da Vinci (1452–1519) first sketched his prototype for a
robotic mechanical knight over five centuries ago. While many centuries later, the namesake
surgical platform has transformed the field of minimally invasive surgery. Da Vinci’s robotic
knight consisted of a complex core of mechanical devices that is thought to be human
powered. The two operating systems of the robot included those with 3° of freedom (legs,
ankles, knees and hips) and those with 4° of freedom (shoulder, elbows, wrists and hands).1
Da Vinci’s mechanical designs were far ahead of the development of any formal design
prints. Similarly, da Vinci’s contribution to anatomy and anatomic illustration were far ahead
of the contemporary scientific work that would occur almost two centuries later.2 (Fig. 1)
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The namesake robotic platform thus captures the essence of Da Vinci’s work including the
novel pursuit of mechanical and robotic design in addition to his pursuit of anatomic
knowledge. (Fig. 2)
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While the concept of robotic design may have been first introduced by Leonardo da Vinci,
the field of ’telesurgery’ or the ability to operate at a remote site with the use of robotic
technology is an emerging area of interest.3 The ability to offer complex minimally invasive
surgery at a site remote from the patient offers the potential to bring a more advanced level
of care in remote areas, potentially saving lives around the world. Not only can this type of
technology help in humanitarian situations with limited access, the military has also pursued
this type of technology to assist in emergency areas.4 This type of ťelecommunication’ and
ťelesurgery’ can be applied in a wide variety of clinical scenarios allowing patients access to
a skilled surgeon remotely. Ongoing research is being conducted to better understand the
amount ot distance possible for remote telesurgery to be feasible.5,6

Author Manuscript

The da Vinci Surgical System (Intuitive Surgical Inc.) was first introduced in 2000 as the
first robotic surgical system approved by the US Food and Drug Administration (FDA). The
surgical platform was eventually approved for use in gynecologic malignancies in 2005. It is
estimated that more than 6 million surgeries have been performed globally using the surgical
platform (www.davincisurgery.com). Since its initial approval, the utilization of the Da Vinci
robotic platform has rapidly increased in the field of gynecologic oncology. While much of
the debate surrounding the adoption of robotic surgery has focused on the cost effectiveness
and the immediate postsurgical outcomes., the benefits of improved ergonomics and
advanced instrumentation are important considerations in surgeon preference (Table 1).
There are few large randomized control trials that investigate the potential discrepancy
between laparoscopic and robotic surgery and also robotic versus open surgery. More
recently, long-term safety concerns regarding oncologic outcomes associated with minimally
invasive surgery (laparoscopy and robotic-assistance) in the management of early cervical
cancer has led the US FDA to issue a ‘safety communication’. In February 28, 2019, the US
FDA cited ‘limited, preliminary evidence’ that the use of robotically assisted surgical
devices for the treatment or prevention of cancers (e.g., breast and cervical) may be
associated with diminished long term-survival. The FDA acknowledged that while
robotically assisted devices allow for quicker recovery and improved surgical technique,
limited studies have been performed to evaluate the specific oncologic clinical outcomes
such as local cancer recurrence, disease free interval, or overall survival.7

Current Indications
Author Manuscript

Cervical cancer
Despite increased access to cervical cancer screening and implementation of human
papillomavirus (HPV) vaccination programs, in 2018 there were approximately 569 847
cases of cervical cancer diagnosed worldwide.8 In the United States, in 2020 there are an
estimated 13,800 new cases and 4,290 disease related deaths.9 For decades, abdominal
radical hysterectomy had been the standard of care for the surgical management of early
FIGO stage cervical cancer with 5-year overall survival rates greater than 80%.10 According
to the National Comprehensive Cancer Network (NCCN) guidelines, radical hysterectomy
J Obstet Gynaecol Res. Author manuscript; available in PMC 2020 July 28.
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remains the standard surgical treatment for early FIGO stage cervical cancer.11 Unlike an
extrafacial hysterectomy, a radical hysterectomy is a complex surgery to perform and teach.
It requires development of the pararectal, paravesical, vesicouterine, and rectovaginal spaces,
ligation of the uterine arteries at their origin along the internal iliac arteries, bilateral
ureterolysis from the pelvic brim to bladder insertion, resection of the cardinal ligaments at
the pelvic sidewall, resection of the uterosacral ligaments at the pelvic floor (sacrum), and
removal of one quarter to one third of the proximal vagina. (3). Bilateral pelvic
lymphadenectomy is also routinely performed as part of a radical hysterectomy.

Author Manuscript

Historically, either an open or minimally invasive (laparoscopic or robotic) surgical approach
was acceptable for radical hysterectomy (4). The first robotic-assisted radical hysterectomy
was reported in 2005 and prompted the beginning of a national trend toward increasing
usage of the robotic platform. Between 2008 and 2015, 3563 radical hysterectomies were
performed based on the National Inpatient Sample (NIS) data, of which 27.5% were
performed using a minimally invasive approach (robotic and laparoscopic).13 Prior studies
have demonstrated that compared to an open approach, minimally invasive (laparoscopic or
robotic) techniques are associated with decreased blood loss, fewer complications, and a
shorter hospital stay.13–16 Additional retrospective studies demonstrated no differences
between robotic-assisted radical hysterectomy and open surgery in regards to recurrence
rates or death (Table 2).12,16

Author Manuscript
Author Manuscript

Following the publication of the Laparoscopic Approach to Cervical Cancer (LACC trial;
Clinicaltrials.gov NCT00614211) in October 2018, the safety of a minimally invasive
approach to radical hysterectomy for early cervical cancer was significantly challenged.
Ramirez et al. published a prospective, randomized trial involving stages IA1
(lymphovascular invasion), IA2, or IB1; with patients who underwent a minimally invasive
approach having a lower rate of disease-free survival at 4.5 years, 86.0% (MIS) compared to
96.5% for open surgery (difference of −10.6 percentage points; 95% CI −16.44.7; p=0.87 for
non-inferiority).17 Of the minimally invasive surgical patients, approximately 84.4%
underwent laparoscopy and 15.6% robot-assisted surgery. The study was prematurely closed
due to an imbalance in deaths between the groups, with differences in overall survival rates
at 3 years 93.8% (MIS) and 99.0% (open). As a companion piece published alongside the
LACC trial, Melamed et al. analyzed the National Cancer Database and Surveillance,
Epidemiology and End Results (SEER) database, demonstrating a decline in relative
survival, with patients who underwent minimally invasive surgery having a worse 4-year
mortality rate of 9.1% compared to 5.3% among those who underwent open surgery. In
subgroup analysis, however, the hazard ratio for death for patients with tumors <2 cm were
statistically similar.18 There remains significant concerns regarding the inherent flaws of a
database study with the biases associated with retrospective analyses. Similarly, Doo et al.
retrospectively evaluated patients with stage IB1 cervical cancer and found no difference in
perioperative complications; however, on multivariate analysis found that robotic radical
hysterectomy or tumor size ≥2 cm (irrespective of surgical approach), were independently
associated with recurrence and death.19
The LACC study highlights several challenges when designing surgical randomized trials
including limited selection criteria of participating surgeons regarding volume and baseline
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outcomes, as well as the standardization of surgical technique, including learning curves.
Radical hysterectomy at baseline is a complex surgery to learn and to teach, however, trying
to perform this surgery using a minimally invasive approach such as laparoscopy can also
lead to significant variation in technique and skill. The LACC trial was performed across 33
centers in 13 countries over a 9-year period. In order for a surgeon to be considered for the
trial, they were required to have a minimum of 10 documented cases as the primary surgeon,
a proven track record with clinical research and hospital privileges and to have submitted 1
unedited surgical video. While there has been significant research showing improved
outcomes with decreased recurrence risk and improved survival in high-volume centers,
surgical volume was not a component in surgeon selection.20 Additionally, the majority of
centers participating in the study were outside of the United States (27/33 centers), where
there is limited oversight and regulation of surgical training compared to the rigor of USbased Gynecologic Oncology training programs.

Author Manuscript
Author Manuscript

An additional challenge included the standardization of surgical technique to improve study
uniformity. In the LACC trial, unlike other surgical trials, there was no standardization or
documentation required by the participating center to assess the performance of appropriate
surgical technique during the study period. For patients randomized to the minimally
invasive arm, it was up to the surgeon to decide between a laparoscopic vs robotic approach,
with 16% of patients undergoing robotic-assisted radical hysterectomy (RRH). Concern for a
lack of uniformity in surgical technique is also supported by the inconsistent finding of
similar postoperative complication rates between the MIS and open radical hysterectomy
groups (25 vs 26%). The similar rates between the two groups is contradictory to many
studies that have demonstrated less blood loss, decreased operative time, fewer blood
transfusions and shorter length of stay with MIS (Table 2). Additionally, key elements in
robotic-assisted surgery that may make this approach more similar to open surgery
compared to laparoscopy, including improved visualization and depth perception with 3D
technology, efficiency in suturing, and more precise dissections were not accounted for
during the study period in either surgeon reported outcomes or pathologic specimen
analysis. While the landmark LACC trial is the highest level of evidence published to date,
currently MIS may still be an acceptable option in select cases. Only 16% of patients
underwent RRH and therefore the extrapolation of data is difficult to interpret. Additional
information is needed to better understand why a minimally invasive approach may be
resulting in worse survival for early stage cervical cancer patients undergoing radical
hysterectomy.
Intrauterine manipulator

Author Manuscript

Following the landmark LACC trial, significant attention has been directed to the specific
surgical techniques used in minimally invasive surgery that could be contributing to the
overall survival differences which includes the use of the intrauterine manipulator. Unlike
open surgery, upward traction on the uterus with the use of an intrauterine manipulator is a
critical step in allowing adequate exposure to safely perform the procedure. Although it has
been hypothesized that the introduction of a uterine manipulator may disrupt tumor and
cause dissemination of cancer cells, this has been refuted by several studies that have failed
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to show a difference in the risk of recurrence or overall survival in the management of
endometrial cancer.21–24
The use of the manipulator for cervical cancer remains slightly more controversial.
Rakowski et al. retrospectively evaluated clinical-data and tumor pathology from open and
robotic-assisted radical hysterectomy cases and found no difference in depth of invasion,
lymphovascular space invasion, or parametrial involvement.25 There are only case reports of
artefactual displacement of CIN III to fallopian tubes during laparoscopic hysterectomy with
use of the intrauterine manipulator; however, this raises a theoretical mechanism of cervical
cancer cell dissemination into the peritoneal cavity.26
Special populations

Author Manuscript

Tumors ≤ 2 cm—A major limitation of the LACC trial was the inability to generalize the
results of the trial to ‘low risk’ cervical cancer cases including tumors of less than 2 cm due
to the trial being under-powered.17 Additionally, in the companion retrospective SEER
database study, there was no survival difference observed between the two surgical methods
for patients with a tumor of less than 2 cm.18 The significance of the 2 cm size cut-off has
also been incorporated in the most updated FIGO cervical cancer staging, suggesting that
this tumor size is of oncologic significance.27 Therefore, given the limited data in patients
with small lesions or < 2 cm, among appropriately selected cases, robotically assisted
surgery may still be an appropriate option after thorough counseling.28,29

Author Manuscript

Fertility sparing—While the standard treatment for early-stage cervical cancer remains
radical hysterectomy with pelvic lymphadenectomy, in patients who desire future fertility,
the option of radical trachelectomy with pelvic lymphadenectomy may be considered.
Several prognostic factors have been identified including histology, LVSI, and deep stromal
invasion when comparing radical trachelectomy to radical hysterectomy for management.30
Tumor size remains controversial with several studies demonstrating conflicting results
regarding outcomes for tumors greater or less than 2 cm.31,32 There remains limited data
regarding the role and outcomes of robotically assisted trachelectomy for cervical cancer.
Currently, a multinational study (IRTA study) assessing differences between an open vs
minimally invasive (robotic or laparoscopic) approach to radical trachelectomy is underway
and will help inform clinical practice.
Endometrial cancer

Author Manuscript

In 2019, there will be an estimated 65,620 new cases of endometrial cancer diagnosed and
12,590 deaths attributed to the disease in the United States.9 The current treatment for earlystage endometrial cancer includes an extrafascial hysterectomy, bilateral salpingooophorectomy with or without a pelvic lymphadenectomy or aortic lymph node sampling.
Unlike cervical cancer, there are several landmark randomized controlled trials that have
evaluated the safety and feasibility of minimally invasive surgery in the management of
endometrial cancer. The Gynecologic Oncology Group LAP2 Study (GOG-LAP2;
Clinicaltrials.gov NCT00002706) was the first trial that demonstrated improved short-term
surgical outcomes including shorter hospital stay and fewer complications with laparoscopy
compared to open surgery.33 Notably, the conversion rate from laparoscopy to open surgery
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was 26%. The study evaluated more than 2500 patients, and reported no difference in overall
survival or recurrence between the two arms.34 Additional studies include the Laparoscopic
Approach to Cancer of the Endometrium (LACE; Clinicaltrails.gov NCT00096408) trial, a
multinational, randomized trial evaluating laparoscopic vs open hysterectomy, which again
showed no difference in disease-free survival or overall survival at 4.5 years.35

Author Manuscript

To date, there are no large randomized trials comparing laparoscopy, laparotomy and
robotic-assisted surgery in the management of endometrial cancers. A systematic review
published in 2010 compared all three surgical modalities (laparoscopy, laparotomy and
robotic assistance) and analyzed eight studies which included 1591 patients. Robotic surgery
was associated with less blood loss compared to both laparoscopy and laparotomy, operative
times were longer with robotic and laparoscopy (however both were similar) than
laparotomy, and length of stay was shorter for minimally invasive approaches. The
conversion rates for laparotomy were 4.0% for robotic-assisted and 9.9% for laparoscopy;
however, this difference was not statistically significant.36 Ran et al. also conducted a metaanalysis in 2014, which included 22 studies that compared the three surgical approaches and
similarly concluded that robotic surgery is safe and may be beneficial over traditional
laparoscopy. They found similar operative times between laparoscopy and robotic
approaches however demonstrated less blood loss and lower conversion rates in robotic
cases.37 In 2019, a Danish study prospectively reviewing outcomes of early-stage
endometrial cancer cases found that abdominal hysterectomy was associated with increased
odds of severe complications compared to a minimally invasive approach (OR, 2.58; 95% CI
1.80–3.70) and was associated with higher mortality compared to laparoscopic and robotic
approaches (laparoscopic HR 1.42; 95%CI 1.02–1.97 and HR 1.70; 95%CI 1.31–2.19,
respectively).38

Author Manuscript

At this time, the evidence continues to support the use of minimally invasive surgery over
laparotomy in the management of early stage endometrial cancer. Several studies have also
suggested a benefit in robotic assistance over laparoscopy, which has been associated with
decreased blood loss and lower conversion rates to open surgery. Additional randomized
studies are needed to assess the long-term oncologic outcomes.
Surgical techniques

Author Manuscript

At our institution, patients are counseled prior to surgery regarding postoperative care
including the option for same-day discharge, which is routinely offered with the exception of
patients with significant medical co-morbidities. Prior to surgery, we use a ‘T-Score’ system
to stratify patients based on several factors: BMI (body mass index), uterine size, history of
abdominal surgeries, vaginal parity and cardiopulmonary reserve (Table 3). This scoring
system allows for appropriate pre-operative counseling on the success of a robotic-assisted
approach. Mechanical bowel prep or antibiotics are not routinely administered prior to
surgery; however, if a para-aortic lymphadenectomy is highly anticipated, Miralax with two
bisacodyl tablets are prescribed to improve visibility. We routinely use a TrenGuard 450
Trendelenburg restraint, which aims to eliminate patients sliding in Trendelenburg position
by placing stabilizing pillows to effectively act as a ‘speed bump’. This technology can
secure patients up to 450 pounds in up to 40° of Trendelburg. In positioning obese patients,
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we recommend a stepwise approach by testing ventilator pressures by incrementally placing
the patient in steep Trendelenburg. For high-risk patients, we also recommend placement of
two peripheral intravenous cannulae prior to tucking arms to improve access in the event of
major bleeding in addition to having a laparotomy tray available in the room. In our
experience, uterine manipulation is helpful to improve visibility and safety. We routinely use
the V-Care disposable uterine manipulator (ConMed).

Author Manuscript
Author Manuscript

For abdominal entry, we anesthetize port sites with 0.5% bupivacaine, and prefer direct entry
method with an 8 mm optical trocar under direct visualization prior to CO2 insufflation. The
four DaVinci robotic ports are 8 mm in size but we recommmend making a 9 mm incision at
each entry site in order to facilitate smooth placement (without excessive pressure due to
skin dystocia) of each cannula using the clear plastic tapered obturator for Xi arms 1, 2, and
4. The placement of the camera port depends on the patienťs body habitus, uterine size, and
the need for para-aortic lymphadenectomy; this port is generally placed 23–27 cm superior
to the pubic symphysis. A zerodegree camera lens is placed in the third arm of the Xi,
monopolar scissors are placed in the fourth arm, a bipolar fenestrated grasper is placed in the
second arm, and a double fenestrated pro-grasp is placed in the first arm. The robot is sidedocked on the left side of the patient. (Fig. 3) After delivery of the uterus through the vagina,
a sterile lap is placed within a glove to occlude the vagina during cuff closure. The
monopolar and bipolar instruments are exchanged for a DaVinci Mega Suturecut Needle
Driver and DaVinci Mega Needle Driver, respectively. 0 vicryl ct-1 sutures x 2 are then
introduced via the assistant port and vaginal cuff closure is accomplished with surgeon’s
knots at each angle and then a running locking stitch towards the center of the cuff where the
sutures are tied together and the needles removed and retrieved through the assistant port.
Following the running of one side of the cuff, the double fenestrated pro-grasp can be used
to maintain upward traction on the cuff and tension on the repair while the surgeon begins
the closure on the opposite side.

Author Manuscript

The placement of the five ports follows a gentle ‘rainbow’ pattern on the abdomen with the
assistant port in the right lower quadrant, directly opposite the DaVinci Xi arm 1 in the left
lower quadrant. When pelvic lymphadenectomy is anticipated, we use a 12 mm AirSeal
System Insufflation (ConMed) and have the console surgeon use the robot to assist the
surgical assistant in closing the 12 mm port with 0 vicryl suture delivered with the Carter
Thomason Fascial Closure Device to prevent hernia formation. When lymphadenectomy is
not planned, we use a 5 mm assisant port and pass 0 vicryl ct-2 sutures x 2 through the Xi
arm 1 port for vaginal cuff closure. Once both sutures have been delivered, the surgeon can
place one needle into the undersurface of the anterior abdominal wall for security and the
surgical assistant replaces the double fenestrated pro-grasp in the Xi arm 1 to facilitate
vaginal cuff closure. The needles are then returned through the Xi arm 1. Finally, for women
with large uteri (12–14 cm or greater) that cannot be delivered transvaginally, a small minilaparotomy incision in the direction of Pfannensteil can be performed with the robot
remaining docked; the uterus is delivered through the incision which is then quickly repaired
and the console surgeon then proceeds to close the vaginal cuff robotically.
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The sentinel lymph node (SLN) algorithm was first incorporated into the NCCN guidelines
for patients with endometrial cancer in 2014.39 Since 2011, there has been a rapid increase
in the use of SLN to detect nodal metastasis, with the most notable increase observed in
women undergoing robotic-assisted hysterectomy.40 The FIRES trial (Clinicaltrials.gov
NCT01673022) is a multicenter, prospective, cohort study with 385 patients enrolled of
which 340 underwent sentinel lymph node mapping using indocyanine green (ICG) and
fluorescence imaging with complete pelvic lymphadenectomy. Of these patients, 41 (12%)
patients had positive notes, of whom 36 had at least one mapped sentinel lymph node. Nodal
metastases were identified in 97% (35/ 36) of the sentinel lymph nodes resulting in a
sensitivity of 97.2% and a negative predictive value of 99.6%.41 Several studies have also
compared the SLN detection rate with ICG compared to blue dye and found a superior
detection rate with ICG (detection rate ICG 90.9% vs blue dye 64.4%, p< 0.0001).42,43
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Author Manuscript

At our institution, for low-risk patients defined as endometrioid adenocarcinoma with <50%
myometrial invasion, we have historically used intraoperative frozen section with Mayo
criteria to triage patients for lymphadenectomy. Patients without myometrial invasion, grade
1 or 2, or with a tumor size ≤2 cm are omitted from undergoing routine lymphadenectomy.
Compared to the Mayo Clinic historical algorithm, the Memorial Sloan Kettering (MSK)
surgical algorithm incorporated SLN mapping in all endometrial cancer staging in addition
to the removal of any suspicious nodes. If there was no mapping on a hemi-pelvis, a sidespecific lymphadenectomy was performed with para-aortic lymphadenectomy at the
surgeon’s discretion. In combination with the MSK algorithm, patients who undergo
unsuccessful mapping of a hemi-pelvis, application of these criteria have been used
selectively to omit them from undergoing lymphadenectomy by Mayo criteria. When
reviewed retrospectively, Leiteo et al. found an increased proportion of patients undergoing
pelvic lymph node excision with the SLN algorithm versus the selective Mayo LND
algorithm, however fewer lymph nodes were removed with the SLN protocol. Overall, both
approaches were without any compromise on short-term oncologic outcomes with similar 3year overall survival.44

Author Manuscript

We use a sentinel lymph node mapping protocol similar to the procedure presented in the
FIRES trial. After induction of anesthesia, a standardized dose of 0.5 mg/mL of ICG tracer
is injected into the cervix. This concentration is achieved by creating a dilution of 1 mL of
the ICG solution (2.5 mg/mL) into 4 mL of sterile water. Using a 22-G spinal needle, 1 cc of
the ICG solution is then injected into the cervix at 3 and 9 o’clock of the ectocervix
approximately 1 cm deep, and an additional 1cc is injectedsuperficially at both sites.
Following entry into the peritoneal cavity using the da Vinci Xi surgical robot, the ICG
tracer can be used to visualize the lymphatic channels. Firefly fluorescence imaging for da
Vinci Surgical System contains an 806 nm laser light source that allows ICG to fluoresce
when illuminated. The fluorescent light is then captured with a special camera device that
allows the ICG to be displayed in the visible light spectrum.45 Mapping is considered
successful after observing a channel from the cervix leading to at least one lymph node in
the hemi-pelvis. Following sentinel lymph node removal, specimens are routinely processed
using the ultra-staging protocol. Sentinel lymph nodes are cut at 3 mm intervals; both
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hematoxylin and eosin (H&E) and pancytokeratin immunohistochemistry staining are
performed. Metastatic disease is defined as either macro- with greater than 2 mm of disease,
micro- with 0.2–2 mm of disease volume, or isolated tumor cells with foci less than 2 mm in
greatest dimension.
Para-aortic lymphadenectomy
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While lymph node status is required for the complete FIGO surgical staging of endometrial
cancer, the routine systematic use of para-aortic lymphadenectomy remains controversial.39
Similar to what has been previously described, we use a center docked trans-peritoneal
approach for para-aortic lymphadenectomy.46–48 The omentum and small bowel are
carefully moved into the left upper quadrant using a Ray-Tec sponge to allow for adequate
visualization. The procedure then starts with an incision of the peritoneum along the right
common iliac artery medial to the ureter. This allows mobilization of the cecum cephaled.
The bedside assistant then laterally retracts the ureter and ovarian vessels. Once the
peritoneum is opened, the psoas muscle and genitofemoral nerve are identified. The
dissection is extended to the bifurcation of the aorta allowing for removal of the common
iliac lymph nodes with development of pedicles using monopolar cautery. The bedside
assistant gently grasps the small bowel peritoneum then to adequately expose the duodenum
and aorta to allow the dissection to continue along the entire surface of the inferior vena cava
to the level of the reflection of the duodenum. The first arm is then used to retract the
duodenum above the renal vein allowing for exposure. The lymph nodes are then dissected
from the left renal vein to the inferior mesenteric artery (IMA) with blunt dissection and
monopolar cautery, with care to avoid perforating lumbar vessels. Dissecting below the IMA
down to the external iliac then completes the lymphadenectomy. We recommend that all
major lymphatic trunks be bipolar cauterized or clipped to minimize the development of
lymphoceles. The left ureter can be identifed by making a small window in the mesentery of
the sigmoid colon.
Special populations

Author Manuscript

Obese patients—Surgery remains the primary treatment for endometrial cancer, and the
approach used has a significant impact on the morbidity and cost associated with the
management of obese patients. Obesity is a wellestablished risk factor for the development
of endometrial cancer.49 In obese patients, similar benefits have been demonstrated with
minimally invasive surgery.50 When evaluating the role of robotic surgery, several
retrospective studies have shown findings consistent with prior studies evaluating
laparoscopy.51–53 In 2008, Gehrig et al. retrospectively reviewed outcomes for obese and
morbidly obese patients undergoing laparoscopy versus robotic-assisted surgery and found
that robotic surgery was associated with shorter operative time (P = 0.0004), less blood loss
(P < 0.0001), increased lymph node retrieval (P = 0.004) and shorter hospital stay (P =
0.01199).52 When evaluating robotic surgery in super-morbidly obese patients (BMI ≥ 50
kg/m2), a retrospective analysis of 168 patients found similar outcomes between
supermorbidly obese patients compared to those with a lower BMI (length of stay, blood
loss, complications, number of lymph nodes), suggesting that robotic surgery is a feasible
option for these patients.54 While robotic surgery in the obese patient with endometrial
cancer is safe and feasible, there is still limited prospective data evaluating the long-term
J Obstet Gynaecol Res. Author manuscript; available in PMC 2020 July 28.
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oncologic outcomes as well as cost effectiveness. For example while, Chan et al.
demonstrated similar outcomes between laparoscopy and robotic-assisted surgical
management in regards to intraoperative and postoperative complications, this study went
further in highlighting the increased charges incurred with robotic surgery versus
laparoscopy.55 For morbidly obese women, we use a step-wise approach of gradiated
placement into steep Trendelenburg position (5 degrees at a time) allowing the patient to
equilibrate as the anesthesiologist monitors tidal volumes and peak pressures. With this
technique we have successfully provided minimally invasive robotic surgery to women with
BMI 60–82.
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Elderly—As life expectancy continues to increase in industrialized nations, we anticipate
increasing rates of gynecologic malignancies diagnosed during later decades in life. This
will likely present more challenging medical and surgical clinical scenarios. Surgery is often
avoided altogether in some high-risk scenarios leading to significant undertreatment.
Although most studies in these populations are retrospective, similar outcomes have been
observed with decreased morbidity associated with laparoscopic surgery.56,57 In a
retrospective analysis of patients from the Gynecologic Oncology Group LAP2 trial
randomizing patients to laparotomy vs laparoscopy, patients greater than 60 years old
experienced significantly less morbidity in the laparoscopic group. Patients across all ages
experienced shorter hospital stay in the laparoscopy group, however, when stratifying by
age, patients ≥60 years old with laparotomy had higher rates of antibiotic administration (P
< 0.001), ileus (P < 0.001), pneumonias (P = 0.48), deep vein thrombosis (P = 0.035) and
arrhythmias (P = 0.01) compared to laparoscopy.58 Leiteo et al. retrospectively evaluated
982 patients who underwent robotic surgery for gynecologic cancer which were stratified by
three age groups: 65–74, 75–84, and ≥ 85 years old. In multivariate analysis, ≥85 years was
independently associated with 90-day mortality (4%), however, overall mortality rate
remained low (0.5%) in the study.59 While much of the data applied to the aging population
is extrapolated from laparoscopic surgery, a similar benefit may be conferred by robotic
surgery; however, randomized data are limited.
Ovarian cancer

Author Manuscript

Despite being an effective form of treatment for endometrial cancer, there are few studies
evaluating the role of robotic-assisted surgery in the initial staging or management of
recurrent ovarian cancer. Currently, 15–25% of patients with ovarian cancer will be
diagnosed at an early stage in the United States, thus complete surgical staging is a critical
component of prognosis and treatment planning. According to NCCN guidelines, complete
surgical staging should include hysterectomy, bilateral salpingooophorectomy,
omentectomy, pelvic and para-aortic lymphadenectomy and peritoneal biopsies.60 Given the
multiquadrant disease distribution, it has been argued that it is insufficient to assess disease
in anatomically challenging locations (lesser sac, Morison’s pouch, mesentery) with MIS,
arguing in favor of open surgery for intra-abdominal evaluation. Given the risk of tumor
spillage and multiquadrant disease, robotic-assisted surgery or MIS is not recommended for
the management of early or advanced stage ovarian cancer.61

J Obstet Gynaecol Res. Author manuscript; available in PMC 2020 July 28.

Clair and Tewari

Page 11

Special population

Author Manuscript
Author Manuscript

Neoadjuvant chemotherapy—There remains a lack of consensus on the superiority of
neoadjuvant chemotherapy followed by interval cytoreductive surgery in the primary
management of ovarian cancer.62–65 The results of the Japan Clinical Oncology Group
JCOG 0602 and the SCORPION trial (Clinicaltrials.gov NCT01461850) are pending in
addition to several ongoing studies (the Trial on Radical Upfront Surgery in Advanced
Ovarian Cancer [TRUST] trial; Clinicaltrials.gov NCT02828618 and Study of Upfront
Surgery Versus Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer
(SUNNY) trial; Clinicaltrials.gov NCT02859038).62,63 Current NCCN guidelines
recommend that neoadjuvant chemotherapy be considered for patients with bulky stage III or
IV disease following an assessment by a gynecologic oncologist.60 Patients often respond to
neoadjuvant chemotherapy and can have a complete response with absent gross residual
disease prior to surgery. In this clinical context, the decision to perform robotic surgery
requires extensive patient counseling and at minimum the following criteria: a normal
CA-125, post-chemotherapy imaging scan without any evidence of disease (including an
absence of ascites), a normal pelvic exam under anesthesia, and laparoscopic evaluation
confirming an absence of visible disease or ascites.

Discussion

Author Manuscript

Robotic-assisted surgery has transformed the field of gynecologic oncology over the last 15
years. This minimally invasive surgical platform has allowed an increasing number of
patients access to the immediate benefits of MIS, including less blood less, shorter hospital
stays, decreased wound complications, and quicker recovery time. Telesurgery and the
ability for surgeons to operate remotely with robotic technology is emerging as an area of
research. Recently, a robotic-assisted percutaneous coronary intervention was successfully
performed at a site 10 miles away in Ahmedabad, India.6 While the field continues to move
forward with more applications, it remains critical in the field of oncology that we continue
to assess the oncologic safety. While many studies during the initial uptake of minimally
invasive techniques consistently demonstrated the improved short-term outcomes for
patients with less morbidity, additional studies including the LACC trial have challenged the
MIS approach citing worse oncologic outcomes. While the FDA has issued a safety warning
in regards to the robotic platform, a very small percentage of women underwent robotic
surgery in the LACC trial. These limitations should be strongly considered when designing
future randomized surgical trials. Additional randomized clinical trials are needed to better
guide gynecologic oncologists in deciding the most appropriate surgical approach to
optimize patient outcomes and appropriately triage patients.
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Figure 1.

Self-portrait of Leonardo da Vinci (1452–1519) and his detailed sketch of female anatomy.
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Figure 2.

Construction of Leonardo da Vinci’s mechanical drummer and mechanical knight, on
display in Berlin. Designed around 1495 for a pageant in Milan, the Robotic Knight
consisted of a life-size suite of armor filled with gears and wheels connected to an elaborate
pulley and cable system allowing for independent motion (sitting down, standing up, moving
its head, lifting its visor, and even playing the drums; rumors also suggested the Knight had
the secret ability to write messages and draw pictures). This prototype was built by roboticist
Mark Rosheim in 2002.
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Figure 3.

The DaVinci Xi Surgical Robot and DaVinci Robot Firefly™ technology demonstrating
sentinel lymphatic mapping for endometrial cancer through which near-infrared light excites
indocyanine green tracer to emit a fluorescent signal. Images from Dr. Tewari’s surgical
practice.
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Advantages of Minimally Invasive Surgery (MIS, laparoscopic and robotic) compared to Laparotomy;
Advantages of Laparoscopy compared to Robotics.

Author Manuscript

MIS

Laparotomy

• Hospitalization not required (decreased hospital costs,
reduced likelihood of contracting hospital-acquired infection)

• Tactile feedback
• Ability to remove large organs intact
• Shorter operating times (reduced OR costs, less exposure to

• Improved cosmesis and reduced risk of cellulitis, superficial
wound separation, need for Wound VAC, hernia formation
requiring mesh, diasthesis, evisceration with acidosis, intraabdominal adhesions with associated discomfort, hazardous
subsequent surgery, and small bowel obstruction
• Less time to reach postoperative milestones (voiding,
ambulation, regular diet, bowel function, pain control,
driving, exercise, return
to work)
• Visualization magnified (less blood loss, fewer blood
transfusions, fewer complications)

inhalational anesthetics, more efficient use of surgeon’s time)
• Expeditious control of catastrophic hemorrhage
• More complex operations possible

Laparoscopic

Robotic

• Haptic feedback

• Ergonomically superior

• Cost-effective

• Intuitive nature

• Fewer and smaller incisions

• Camera stabilization

• Avoidance of prolonged Trendelenberg

• Wristed instrumentation with improved dexterity (precision with dissection,
ease of suturing, facilitates development of surgical planes in areas riddled with
disease)

• Flexibility in instrument configuration

• Motion dampening sensors (tremor filtration)
• Depth perception due to 3D camera (less blood loss, reduced transfusions,
reduced complications)
• May facilitate MIS for morbidly obese
• Lower conversion rate to open surgery
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Author Manuscript
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Case control

Prospective

Retrospective

Prospective

Retrospective

Retrospective

Prospective

Population-based
retrospective

Retrospective casecontrol

Meta-analysis

Retrospective casecontrol

Retrospective

Retrospective casecontrol

Retrospective casecontrol

Retrospective cohort

Long-term follow-up
of prospective study

Retrospective casecontrol

Magrina 2008

Nezhat 2008

Maggioni 2009

Cantrell 2010

Soliman 2011

Tinelli 2011

Wright 2012

Kim 2014

Shazly 2014

Kong 2016

Sert 2016

Mendivil 2016

Zanagolo 2016

Diver 2017

Pellegrino 2017

Shah 2017

Study design

Boggess 2008

Source/year
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RRH vs ARH

RRH vs LRH

RRH vs LRH vs
ARH

RRH vs ARH

RRH vs LRH vs
ARH

RRH vs ARH

RRHvs LRH vs
ARH

RRHvs LRH vs
ARH

RRH vs LRH

RRH vs LRH vs
ARH

RRH vs LRH

RRH vs LRH vs
ARH

RRH vs ARH

RRH vs ARH

RRH vs LRH

RRH vs LRH vs
ARH

RRH vs ARH

Groups

Stage IA1–IB2 cervix

Stage IA1–IIA2
cervix

Stage IA–IIB cervix

Early stage cervix

Early stage cervix

Early stage cervix

Stage IB–IIA cervix

Stage IA1–IIA cervix

Stage I–IIA cervix

Cervix (stage
unknown)

Stage IA1–IIB cervix

Stage IA1–IIBA
cervix and corpus

Stage IA1–IIB cervix

Stage IA2–-IIA
cervix

Stage IA1–IIA cervix

Stage IA2–IB2 cervix
and corpus

Early stage cervix

Disease

311

52

383

307

146

491

128

4013

92

1894

99

95

127

80

43

57

100

Total

109

34

71

203

58

259

20

1013

23

67

23

34

63

40

13

18

51

RRH

—

18

30

—

49

—

108

710

69

217

76

31

—

—

30

18

—

LRH

Number of patients

202

—

282

104

39

232

—

2290

—

1610

—

30

64

40

—

21

49

ARH

RRH associated with less EBL, LOS, complications; no difference in
PFS or OS

RRH associated with decreased EBL, similar operative time; OS at 59
months (RRH 100% vs LRH 83%)

Similar OS and recurrence between MIS and ARH, ARH associated with
increased EBL and LOS

RRH associated with less EBL, LOS; no difference in OS or PFS at 3
years

ARH associated with increased LOS, EBL; LRH shorter operative times;
no difference in OS or PFS

RRH less EBL, LOS, longer operative time; recurrencea and death rates
similar at 3 years

Disease recurrence higher in RRH/LRH with intracorporeal colpotomy
vs LRH vaginal colpotomy (16 vs 5.1%, P = 0.057)

RRH superior to ARH with lower EBL, LOS, wound and febrile
morbidities; RRH comparable to LRH in short-term outcomes

RRH associated with less EBL, longer operative time; no difference in
complications or 3-year recurrence free survival

ARH associated with increased perioperative complications, MIS
associated with lower transfusion rates and LOS

No difference in blood loss, LOS, recurrence rates, longer operative time
for LRH

MIS associated with less EBL, LOS; trend toward higher conversion rate
in LRH compared to RRH, shorter operative time with ARH

No statistical difference in PFS or OS compared to historical cohort of
ARH

RRH associated with decreased EBL and LOS, increased operative time;
no difference in complications

RRH similar to LRH in operative time, blood loss, hospital stay and
oncologic outcome

First study comparing RRH and LRH to ARH, shorter operating times
for RRH with similar outcomes to LRH

First case series of RRH, RRH associated with shorter operative time,
LOS, less blood loss, similar complication rate

Significance

Author Manuscript

Selected publications of robotic surgery in cervical cancer

Author Manuscript
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Author Manuscript

Retrospective case
series

Retrospective

Meta-analysis

Retrospective

Population-based
cohort

Population-based
retrospective

Siesto 2019

Matanes 2019

Zhang 2019

Doo 2019

Alfonzo 2019

Cusimano 2019

RRH vs LRH vs
ARH

RRH vs ARH

RRH vs ARH

RRH vs LRH vs
ARH

RRH vs ARH

RRH/LRH vs ARH

RRH/ LRH vs ARH

RRH vs LRH vs
ARH

RRH vs LRH vs
ARH

RRH vs LRH

Cervix

Stage IA1–IB cervix

Stage IB1 cervix

Cervix

Early stage cervix

Stage IA–IIA1 cervix

Stage IA2–IB1

Stage IA1–Ib1 cervix

Stage I–II cervix

Stage IA2–IB2 cervix

Early stage cervix

958

864

105

2197

98

91

2461

631

2100

210

125

Total

49

628

49

932

74

91

978

269

n/a

70

65

RRH

424

—

—

373

—

—

247

49

n/a

140

60

LRH

Number of patients

483

236

49

892

24

—

1236

312

n/a

—

—

ARH

MIS associated with increased rates of death and recurrence compared to
OH in patients with IB disease but not IA disease

No difference in 5-year OS or DFSbetween open and robotic groups

No difference in recurrence risk, PFS or OS; however in tumors ≥2 cm
higher risk of recurrence, in RRH, higher risk of recurrence (30 vs 8%, P
= 0.006) and shorter PFS (HR 0.31)

12 studies included, RRH less EBL, shorter LOS compared to ORH; no
difference between RRH and LRH in tumor recurrence

Recurrence rate lower in RRH (17% vs 7%); no difference in OS or PFS
at 46 months

RRH 40 month follow-up, DFS 90.4% (95%CI 85.3–95.6) and OS
94.5% (95%CI 91.8–97.2)

Increased 4 year mortality in LRH/RRH group (9.1%) compared to ARH
(5.3%)

Disease free survival lower in LRH/RRH (86%) compared to ARH
(96.5%) and overall survival (93% vs 99%)

17 studies included; RRH and LRH lower EBL and LOS compared to
ARH

RRH associated with longer operative time; no difference in 3-year DFS
or OS

RRH associated with longer operative time; OS lower in RRH compared
to LRH (P = 0.0762), no difference in recurrence pattern (P = 0.7)
however peritoneal recurrence only in RRH group

Significance

Abbreviations: ARH, abdominal radical hysterectomy; LRH, laparoscopic radical hysterectomy; RRH, robotic-assisted radical hysterectomy.

Population-based
cohort study

Melamed 2018

Meta-analysis

Jin 2018

Prospective phase III
RCT

Retrospective

Gallotta 2018

Ramirez 2018

Retrospective

Chong 2018

Disease

Author Manuscript
Groups

Author Manuscript

Study design

Author Manuscript

Source/year
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Author Manuscript

Author Manuscript

≥45

2

>13

11–13

≤10

Uterine size (cm)

Midlline vertical or other exploratory

LTC/S only and/or LSC

None

Abdominal surgeries

C/S only

No prior vaginal births

Prior vaginal birth(s)

Vaginal parity

Significant co-morbities (eg, history of cardiac arrest, severe hypertension, aortic
stenosis, pulmonary fibrosis, etc)

Mild-to-moderate medical co-morbidities (eg, mild hypertension)

No significant medical co-morbidities

Cardiopulmonary reserve

BMI, body mass index; C/S, cesarean section; LSC, laparoscopy; LTC/S, low transverse cesarean section, The T score (Tewari score) is calculated by adding the points for the five components listed in the
table.

≤30

31–44

1

BMI

0

Points

‘T-score’ preoperative assessment for minimally invasive approach to hysterectomy

Author Manuscript
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